Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$11.32 USD
+0.37 (3.38%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $11.33 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 121 - 140 ( 364 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Catalyst Rich 2020 - Expecting Phase 3 VGX-3100 - Several Phase 2 Results
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results Reported; Momentous Data Readouts in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-5401 Combo Regimen Positive Interim Glioblastoma Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Grant Awarded to Address Antimicrobial Resistance Using dMAb; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Study in Anal Dysplasia Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Anticipating Multiple Near-Term Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 1 MERS Vaccine Results Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Focus on Core Clinical Programs; Cash Burn Reduced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Geneos Therapeutics Spinout Advances Personalized Cancer Vaccine Into First-in-Human Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
VGX-3100 Vulvar Dysplasia Phase 2 Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R